Accelerating innovation to deliver better treatments

Animol Discovery is accelerating the identification of innovative medicines for unmet needs in animals by using a disruptive approach to small molecule discovery and development. We achieve this by combining genomics analysis, the power of DNA-encoded libraries, and artificial intelligence/machine learning technologies. As a result, Animol Discovery can identify more effective and safer pharmaceuticals which are tailored to the needs of veterinary patients.

Accelerating innovation to deliver better treatments

Animol Discovery is accelerating the identification of innovative medicines for unmet needs in animals by using a disruptive approach to small molecule discovery and development. We achieve this by combining genomics analysis, the power of DNA-encoded libraries, and artificial intelligence/machine learning technologies. As a result, Animol Discovery can identify more effective and safer pharmaceuticals which are tailored to the needs of veterinary patients.

better treatments

Innovate until every

animal is well

At Animol Discovery we are passionate about the health of animals. Companion and farm animals deserve the best possible medicines, and we are committed accelerating innovation in their care. Our approach enables us to bring novel treatments substantially faster to our patients without compromising on safety and efficacy.

Innovate until every animal is well

At Animol Discovery we are passionate about the health of animals. Companion and farm animals deserve the best possible medicines, and we are committed accelerating innovation in their care. Our approach enables us to bring novel treatments substantially faster to our patients without compromising on safety and efficacy.

until every animol is well

Technology

Small molecules

Small molecule pharmaceuticals have been the backbone of medical treatment since the inception of pharmacology. Scientific progress in drug discovery…

Releasing the potential of pharmaceuticals in animal health

Animol Discovery, based on the pioneering work of our exclusive partners X-Chem and ZebiAI, has developed a platform that is unique in the Animal Health industry…

Pipeline

Since initiation of the first project in June 2020 Animol Discovery has completed several screens and has moved these projects to lead optimization…

Latest news updates

  • 15 Mar 2021
    Former Head Of Business Development, Alliances And Solutions At Zoetis, Michelle Haven, Joins Animol Discovery Board Of Directors

    Animol Discovery, a biotechnology company delivering break-through novel small molecule drugs for the animal health industry based on its unique technology platform, announced today that Michelle Haven has joined the company’s Board of Directors. Dr. Haven, currently Senior Adviser and Venture Partner at Anterra Capital, comes to Animol with more than 25 years of experience in the animal health industry, most recently as Senior Vice President for Business Development, Alliances and Solutions at Zoetis, Inc. Prior to that, she led global pharmaceutical and biological research at Pfizer Animal Health for several years and contributed to the development of multiple successful products.

  • 01 Jan 2020
    Animol Discovery Announces $6 Million Seed Financing From Anterra Capital To Build High Value Pipeline Of Break-through Small Molecules For Animal Health

    Animol Discovery, Inc. today announced receiving $6 million in seed financing from Anterra Capital to identify and develop its own pipeline of break-through proprietary veterinary small molecules.  Based on a unique platform of DNA-encoded libraries (DEL) in combination with advanced machine learning/AI, Animol will deliver unprecedented number of novel compounds in the areas of antiparasitics and therapeutics.  Over the coming year Animol Discovery will identify and subsequently develop medicines for companion animals and livestock, either by itself or in cooperation with Animal Health companies.